Race does not explain genetic heterogeneity in pharmacogenomic pathways.

ABSTRACT:

Introduction

Polymorphic alleles in the human genome have been identified as affecting numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is impractical. Since many polymorphisms occur at varying rates in different racial groups, we investigated whether a patient's race could predict presence of drug-relevant genetic variants well enough to be used as a substitute for individual genotyping.

Methods

We performed hierarchical clustering and principal components analysis on tagSNPs from three pathways (irinotecan, 5-fluorouracil and insulin) across 270 individuals from four racial groups available from the International HapMap Project.

Results

For the drug pathways, irinotecan and 5-fluorouracil, individuals from each race were

SUBMITTER: Yen-Revollo JL 

PROVIDER: S-EPMC2632586 | biostudies-literature | 2008 Nov

REPOSITORIES: biostudies-literature